Sihuan Pharma’s Polycaprolactone Microsphere Filler Gains NMPA Approval
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has received Category III...
Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand
Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...
WuXi XDC Partners with MABSOFT to Advance Innovative ADC Development
China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi...
Guojian Qingke Biomedical Gains NMPA Approval for 3D MSCs in Stroke Trials
China-based Guojian Qingke Biomedical Technology (Beijing) Co., Ltd. announced that it has received tacit clinical...
Gan & Lee Pharmaceuticals Secures Pakistan Approval for Insulin Glargine Cartridge
Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its...
Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s
US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...
NMPA Reduces Influenza Vaccine Batch Release Time to 45 Working Days
The National Medical Products Administration (NMPA) has issued a notification reducing the time limit for...
Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...
Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program
US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...
Jiangxi Rimag Lists CT Chest Lesion Data on Shanghai Data Exchange
China-based medical imaging expert Jiangxi Rimag Group Co., Ltd (HKG: 2522) has announced the successful...
Novartis’ Fabhalta Approved in China for C3 Glomerulopathy
Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...
Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis
Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...
China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025
The General Office of China’s National Health Commission has issued a notice outlining key tasks...
Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...
AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO
On April 2, 2025, China-based AccurEdit Therapeutics (Suzhou) Co., Ltd., a specialist in gene editing...
Organon Acquires U.S. Rights to TOFIDENCE from Biogen
Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...
Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China
Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...
ChemPartner Plans Share Issuance to Raise Up to 316.3 Million Yuan
On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a...
Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation
Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...
Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...